Janux Therapeutics Inc (JANX) Price & Analysis

Compare

475 Followers

JANX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$21.73 - $71.71

Previous CloseN/A

Volume1.13M

Average Volume (3M)689.70K

Market Cap

$1.40B

Enterprise Value$456.12M

Total Cash (Recent Filing)$996.01M

Total Debt (Recent Filing)$22.19M

Price to Earnings (P/E)―

Beta1.89

Next Earnings

Nov 11, 2025

EPS Estimate

-0.61

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.55

Shares Outstanding60,093,933

10 Day Avg. Volume791,194

30 Day Avg. Volume689,702

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.33

Enterprise Value/Revenue-56.50

Enterprise Value/Gross Profit-44.85

Enterprise Value/Ebitda-3.17

Forecast

1Y Price Target

$73.53

Price Target Upside216.53% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering19

Bulls Say, Bears Say

Bulls Say

Market PotentialSignificant market opportunity is seen for lead candidate JANX007 as it moves into expanded studies with a derisked platform.

Product DevelopmentJANX007 data shows promising PSA response rates, RECIST ORR data, and preliminary durability, outpacing competitive efficacy benchmarks.

Strategic PartnershipsJanux announced receipt of a $10M payment from Merck for achieving a clinical milestone for the partnered TRACTr program.

Bears Say

Clinical Data ExpectationsUncertainty regarding the nature and details of the 2H Ph 1 data disclosures somewhat tempers expectations for the catalyst.

Data Disclosure UncertaintyUncertainty regarding the nature and details of the 2H Ph 1 data disclosures somewhat tempers expectations for the catalyst.

Janux Therapeutics Inc News

Janux Therapeutics initiated with an Overweight at Barclays

Barclays initiated coverage of Janux Therapeutics (JANX) with an Overweight rating and $47 price target Janux has shown...

13d ago

JANX

Janux Therapeutics initiated with an Overweight at Barclays

Barclays analyst Etzer Darout initiated coverage of Janux Therapeutics (JANX) with an Overweight rating and $47 price target...

13d ago

JANX

Synopsys downgraded, Oracle upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

19d ago

AME

BWA

Janux Therapeutics initiated with a Buy at Truist

Truist initiated coverage of Janux Therapeutics (JANX) with a Buy rating and $100 price target The firm believes...

19d ago

JANX

Janux Therapeutics resumed with a Buy at Stifel

Stifel resumed coverage of Janux Therapeutics (JANX) with a Buy rating and $45 price target The firm views...

20d ago

JANX

Janux Therapeutics initiated with a Buy at Guggenheim

Guggenheim analyst Brad Canino initiated coverage of Janux Therapeutics (JANX) with a Buy rating and $72 price target...

25d ago

JANX

Janux Therapeutics initiated with a Buy at Guggenheim

Guggenheim analyst Brad Canino initiated coverage of Janux Therapeutics (JANX) with a Buy rating and $72 price target...

26d ago

JANX

Janux Therapeutics Announces Departure of Chief Strategy Officer

The latest update is out from Janux Therapeutics Inc ( ($JANX) ). Byron Robinson, Ph.D., previously a named...

10d ago

JANX

Buy Rating for Janux Therapeutics Inc: Promising Oncology Innovations and Strategic Advancements

Stephen Willey, an analyst from Stifel Nicolaus, has initiated a new Buy rating on Janux Therapeutics Inc (JANX)....

20d ago

JANX

Piper starts Janux Therapeutics with an Overweight on ‘best-in-class’ potential

As previously reported, Piper Sandler initiated coverage of Janux Therapeutics (JANX) with an Overweight rating and $42 price...

1M ago

JANX

Janux Therapeutics initiated with an Overweight at Piper Sandler

Piper Sandler analyst Kelsey Goodwin initiated coverage of Janux Therapeutics (JANX) with an Overweight rating and $42 price...

1M ago

JANX

Buy Rating for Janux Therapeutics Driven by Promising Tumor-Conditional Masking Platform and Strategic Collaborations

Analyst Jeffrey La Rosa of Leerink Partners maintained a Buy rating on Janux Therapeutics Inc, with a price...

2M ago

JANX

Promising Future for Janux Therapeutics: Buy Rating Backed by Strong Clinical Profile and Strategic Trials

In a report released today, Alec Stranahan from Bank of America Securities maintained a Buy rating on Janux...

2M ago

JANX

Promising Developments and Strategic Expansion at Janux Therapeutics: Analyst Sets $70 Price Target

Janux Therapeutics Inc, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Swayampakula Ramakanth...

2M ago

JANX

JANX FAQ

What was Janux Therapeutics Inc’s price range in the past 12 months?

Janux Therapeutics Inc lowest stock price was $21.73 and its highest was $71.71 in the past 12 months.

What is Janux Therapeutics Inc’s market cap?

Janux Therapeutics Inc’s market cap is $1.40B.

When is Janux Therapeutics Inc’s upcoming earnings report date?

Janux Therapeutics Inc’s upcoming earnings report date is Nov 11, 2025 which is in 43 days.

How were Janux Therapeutics Inc’s earnings last quarter?

Janux Therapeutics Inc released its earnings results on Aug 07, 2025. The company reported -$0.55 earnings per share for the quarter, missing the consensus estimate of -$0.472 by -$0.078.

Is Janux Therapeutics Inc overvalued?

According to Wall Street analysts Janux Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Janux Therapeutics Inc pay dividends?

Janux Therapeutics Inc does not currently pay dividends.

What is Janux Therapeutics Inc’s EPS estimate?

Janux Therapeutics Inc’s EPS estimate is -0.61.

How many shares outstanding does Janux Therapeutics Inc have?

Janux Therapeutics Inc has 60,093,933 shares outstanding.

What happened to Janux Therapeutics Inc’s price movement after its last earnings report?

Janux Therapeutics Inc reported an EPS of -$0.55 in its last earnings report, missing expectations of -$0.472. Following the earnings report the stock price went up 1.107%.

Which hedge fund is a major shareholder of Janux Therapeutics Inc?

Currently, no hedge funds are holding shares in JANX

Janux Therapeutics Inc Stock Smart Score

Neutral

Fundamentals

Return on Equity

-12.82%

Trailing 12-Months

Asset Growth

49.29%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Janux Therapeutics Inc

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.

Janux Therapeutics Inc (JANX) Earnings & Revenues

Historic Earnings Reports

JANX Stock 12 Month Forecast

Average Price Target

$73.53

▲(216.53% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"$21","66":"$66","111":"$111","156":"$156","201":"$201"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":200,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$200.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":73.53,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$73.53</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$25.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,66,111,156,201],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.86,36.48615384615384,50.11230769230769,63.738461538461536,77.36461538461538,90.99076923076922,104.61692307692307,118.24307692307691,131.86923076923074,145.49538461538458,159.12153846153842,172.74769230769226,186.37384615384616,{"y":200,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.86,26.757692307692306,30.655384615384616,34.55307692307692,38.45076923076923,42.348461538461535,46.246153846153845,50.143846153846155,54.041538461538465,57.93923076923077,61.83692307692308,65.73461538461538,69.63230769230769,{"y":73.53,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.86,23.024615384615384,23.189230769230768,23.353846153846153,23.518461538461537,23.68307692307692,23.847692307692306,24.012307692307694,24.176923076923078,24.341538461538462,24.506153846153847,24.67076923076923,24.835384615384616,{"y":25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":46.98,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.5,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.39,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.18,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.54,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.48,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.89,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.81,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.05,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.01,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.22,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.56,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.86,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >